← Leaderboards
Nathan G Congdon
Johns Hopkins University
$1,903,324
Attributed
$1,903,324
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,903,324 · 2
By mechanism
R01$1,170,421 · 1
K23$732,903 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Richard D Semba$20,161,870
- Richard Anthony Edward Edden$15,962,994
- Barbara S Hawkins$9,860,273
- Hugo W Moser$5,176,943
- Elizabeth A Eipper$13,280,286
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectCataractAntioxidantsLongitudinal Human StudyClinical ResearchPathologic ProcessQuestionnairesRetinoidsSolar RadiationTocopherolsClinical TrialsVitamin TherapyAscorbateDiet TherapyDisease /Disorder Prevention /ControlExperimental DesignsEye Disorder DiagnosisNutrition Related TagGenetic SusceptibilityAlcoholism /Alcohol AbuseDiabetes MellitusDisease /Disorder OnsetFamily GeneticsGender Difference
Grant awards (7)
CLINICAL TRIALS IN CATARACT PREVENTION$188,110
K23 · FY2003 · EY
GENETICS OF AGED RELATED CATARACTS IN SALISBURY MARYLAND$400,051
R01 · FY2002 · AG
CLINICAL TRIALS IN CATARACT PREVENTION$183,261
K23 · FY2002 · EY
GENETICS OF AGED RELATED CATARACTS IN SALISBURY MARYLAND$390,207
R01 · FY2001 · AG
CLINICAL TRIALS IN CATARACT PREVENTION$178,552
K23 · FY2001 · EY
GENETICS OF AGED RELATED CATARACTS IN SALISBURY MARYLAND$380,163
R01 · FY2000 · AG
CLINICAL TRIALS IN CATARACT PREVENTION$182,980
K23 · FY2000 · EY